AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04817189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)
Description: Standard of care will be administered on Day 1 of each cycle.
Study NCT04817189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 8 mg (oral) or equivalent IV dose
Description: Dexamethasone (8 mg) will be administered on Day 1 of each cycle.
Study NCT05887063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia Awareness Course UK
Description: An online course delivered to a small group of informal caregivers in between 3 and 4 hours. The course is made up of three modules: what is dementia, positive engagement and caring for someone with dementia. The course is delivered by one facilitator and includes teaching, discussions and activities.
Study NCT04817189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, 8 mg (oral) or equivalent IV dose
Description: Dexamethasone (8 mg) will be administered on Day 1 of each cycle.
Study NCT06479239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR FPBMC
Description: Participants will receive 8 weekly infusions of EGFR FPBMC, then 8 additional infusions every 2 weeks.
Study NCT06095037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful yoga
Description: 12 week mindful yoga intervention
Study NCT06555159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise prescription: Continuous aerobic training (jogging, swimming, static cycling)
Description: Aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate. (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload
Study NCT06555159 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group: Continuous aerobic physical exercise
Description: Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax, keeping this intensity for the 8 week intervention period.
Study NCT06095037 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: 12 week psychoeducation sessions
Study NCT05024344 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
Study NCT05024344 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
Study NCT05024344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
Study NCT05024344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
Study NCT04841590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention of the experimental group (EG)
Description: Treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
Study NCT05796505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADVANCE Steering Committee interventions
Description: Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
Study NCT04841590 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group (CG)
Description: Subjects in the control group (CG) will not receive any treatment
Study NCT04801576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flouride in mouthrinses
Description: Custom made toothpastes and mouthrinses that do or do not contain flouride as sodium fluoride in different concentrations.
Study NCT04801576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthrinse
Description: Mouthrinses without flouride
Study NCT06357260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin and Carbamazepine
Description: Carbamazepine+pregabalin with fixed dose of pregabalin 75mg BD and carbamazepine being titrated as per patients's need
Study NCT06357260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Carbamazepine with dose of Carbazmaepine being titrated as per patients's need
Study NCT05754424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT278
Description: Concentrated rapid acting insulin aspart
Study NCT05754424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT278
Description: Concentrated rapid acting insulin aspart
Study NCT05754424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoRapid
Description: Rapid-acting insulin aspart
Study NCT05754424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid
Description: Rapid-acting insulin aspart
Study NCT05754424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin R 500 UNT/ML Injectable Solution
Description: Regular human insulin
Study NCT05754424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin R 500 UNT/ML Injectable Solution
Description: Regular human insulin
Study NCT06468423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox (DFX)
Description: Oral DFX at a dose of 30mg/kg daily advised for a duration of 6 months.
Study NCT06468423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO)
Description: DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week for a duration of 6 months.
Study NCT05570435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.
Study NCT05570435 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection
Description: Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.
Study NCT06300489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposomes+capecitabine
Description: Radiotherapy：IMRT DT 50Gy/25Fx. Capecitabine: 625mg/m2 bid po d1-5 qw. For patients are double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)，the intial dose of Irinotecan liposomes is 25mg/m2 weekly，for four weeks。 This study stratify cases by the 3+3 rule according to UGT1A1 \* 6 and UGT1A1 \* 28 phenotypes. Three cases were enrolled in each dose group, and if there was no DLT, they were promoted to the next dose group（an increase of 5mg/m2）; If there is 1 case of DLT, 3 cases will be reenrolled in the same dose group. If there is no new occurrence of DLT, it will be promoted to the next dose group. Otherwise, the study will be terminated; If there are 2 cases of DLT, the study will be terminated, and the previous dose group will be the maximum tolerated dose (MTD).
Study NCT04906278 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Foley catheter balloon
Description: A Cusco speculum will be placed and a 16F Foley catheter will be inserted into the cervix using ring forceps. Then the balloon will be inflated with 40 ml of saline and it will be pulled out to ensure the balloon covered the internal os of the cervix
Study NCT04906278 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Amniotomy
Description: Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip. Care should be taken to protect maternal vaginal tissues from the forceps. Once the forceps reach the amniotic sac, the tip is pushed up against the sac with the index or middle finger of the internal hand to pierce the membranes. The nature of amniotic fluid will be checked.
Study NCT04906278 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.
Study NCT06053762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-facilitated tobacco cessation
Description: Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes
Study NCT06053762 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-navigated tobacco cessation
Description: Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves. Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
Study NCT05685277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg
Description: Ramipril/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
Study NCT05685277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tritace® Plus tablet 10 mg/25 mg
Description: Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
Study NCT05118516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC43F
Description: One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
Study NCT06277115 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP)
Description: Nocturnal continuous positive airway pressure therapy is the gold standard treatment for symptomatic OSA. It provides positive pressure via a nasal or oronasal mask to prevent upper airway collapse during sleep.
Study NCT06405633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucelotide
Study NCT06389123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Description: Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
Study NCT05378802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different modes of mechanical ventilation
Description: Four different ventilation modes were performed one by one and respiratory parameters were recorded.
Study NCT05378802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different modes of mechanical ventilation
Description: Four different ventilation modes were performed one by one and respiratory parameters were recorded.
Study NCT04956679 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: carbon 13 breath test
Description: Patients with positive Helicobacter pylori infection were determined by carbon 13 breath test ,The diagnosis and treatment of positive patients were followed up without other intervention.
Study NCT05698069 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Modulation Index
Description: A 18 item questionnaire assessing patients' pain characteristics for the detection of disordered pain modulation processes.
Study NCT05698069 — intervention group
Intervention type: OTHER
Intervention: Pain Detect
Description: A questionnaire that was validated for the assessment of neuropathic pain
Study NCT05698069 — intervention group
Intervention type: OTHER
Intervention: Central sensitization inventory
Description: A questionnaire developed for the detection of central sensitization.
Study NCT05816486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunobiogram
Description: This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.
Study NCT04719377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter placement
Description: catheter placement
Study NCT04719377 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: catheter placement
Description: catheter placement
Study NCT05074836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula milk
Description: Brand name: Yili (QQ star formula milk);~Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;~Dosage: 195ml\*2/d;~Intervention duration: 12 months
Study NCT05074836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular milk
Description: Brand name: Yili；~Type: regular milk (pure milk);~Dosage: 195ml\*2/d;~Intervention duration: 12 months
Study NCT05074836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control foods
Description: Brand: N/A;~Food type: grain foods (e.g., bread);~Dosage: 20-40g \* 2/d grain foods~Intervention duration: 12 months
Study NCT05148897 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: a self-administered questionnaire. Based on extensive literature review no questionnaire was found that specifically related to knowledge evaluation. The basic theme of the questionnaire was taken from Diabetes Knowledge Questionnaire (DKN), a well validated tool for knowledge assessment among type 1 and type 2 diabetes mellitus patients. Some modifications were made and new questions particularly related to GDM were included.
Study NCT05931744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: after application of topical vasoconstrictor packs into both nasal cavities, using 1 cc 28 gauge needle sterile syringe, one pack of budesonide ampule 0.5 mg/2ml was injected into visible polyps on both cavities 1 ml in each cavity weekly for 5 consecutive weeks
Study NCT05931744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: patients given oral prednisone 1 mg/ kg with max. dose 70 mg/d divided into two doses for 3 days then tapered gradually for two weeks
Study NCT05931744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: saline intrapolyp injection
Study NCT04614675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal soft tissue procedure with TALR
Description: TALR group: Transarticular lateral release as the distal soft tissue procedure
Study NCT04614675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal soft tissue procedure with PCLR
Description: PCLR: Percutaneous soft tissue procedures as the distal soft tissue procedure
Study NCT06498752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody consolidation therapy
Description: PD-1 monoclonal antibody-based consolidation therapy for 1 year after completion of radiotherapy (or combination chemotherapy up to 4 cycles if less than 4 cycles of chemotherapy). Specific dosing: PD-1 monoclonal antibody, 200mg every 3 weeks.
Study NCT05328856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hansgrohe prototype
Description: Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out with a mixing function for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds
Study NCT04577573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognition glove
Description: The investigators have developed and tested a functional prototype of an instrumented glove to alert the user about secure grasp of objects. Onboard force and flex sensors provide inputs to a machine learning algorithm (artificial neural network, ANN) to estimate secure grasp based on previously collected training data. The glove enhances agency by alerting the user to secure grasp through sensory feedback modules (visual - LED, audio - beeper, tactile - vibrator).
Study NCT04577573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cognition glove
Description: The investigators have developed and tested a functional prototype of an instrumented glove to alert the user about secure grasp of objects. Onboard force and flex sensors provide inputs to a machine learning algorithm (artificial neural network, ANN) to estimate secure grasp based on previously collected training data. The glove enhances agency by alerting the user to secure grasp through sensory feedback modules (visual - LED, audio - beeper, tactile - vibrator).
Study NCT04577573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensory brace
Description: A a size- and position-adjustable arm brace with weight-support capability and housing for vibration motors and EMG sensors. Position adjustment allows for physical therapists to find and recommend arm postures that are clinically relevant to~each person. The participant can then isometrically push/resist against the brace to strengthen target muscles while performing VR reach-to-touch. The person will receive visual feedback from the virtual environment to train movement performance and vibrotactile feedback at tendons to subconsciously adjust their muscle activation patterns
Study NCT06112015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulgarian split squat exercise variations
Description: The participants performed 4 different sessions of Bulgarian split squat exercises-Bulgarian split squat with trunk flexion (BSS flexion), Bulgarian Split squat with trunk neutral (BSS neutral), suspension based Bulgarian split squat with trunk flexion (SBSS flexion), suspension based Bulgarian split squat with trunk neutral (SBSS neutral)-with EMG recordings being taken from the dominant extremity throughout each session. For each exercise, participants were instructed to perform three successful repetitions. Between each repetition, there was a 30-second break, and there was at least 10 minutes in between each of the 4 exercises. The movement was standardized by a metronome. The modified Borg scale was used to ensure that fatigue did not occur before each exercise since it was believed that fatigue could affect exercise performance. When scores reported using the modified Borg scale were 1 or lower, exercise recording was started.
Study NCT04843306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Relaxation coaching will be used in this study.
Study NCT04843306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Breathing Control Technique
Description: Active breathing control (ABC) requires patients to reproducibly perform multiple deep-inspiratory breath holds during treatment.
Study NCT04843306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Breathing Control Technique
Description: Active breathing control (ABC) requires patients to reproducibly perform multiple deep-inspiratory breath holds during treatment.
Study NCT05283395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Description: Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension